Johnson & Johnson (NYSE:JNJ) Number of Hedge Fund Holders: 81 Johnson & Johnson (NYSE:JNJ) researches and develops, manufactures, and sells various products in the healthcare field. This company ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against othe ...

Johnson & Johnson (Symbol: JNJ) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.2% yield, as ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...

Johnson & Johnson (JNJ) is scheduled to report earnings on April 15, 2025. The last reported earnings were for reported on January 22, 2025 for Q4.

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA ...

Johnson & Johnson’s medtech leader said Wednesday that the company is now working with the Food and Drug Administration about safety risks tied to its Varipulse pulsed field ablation device. Tim ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...

FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral antidepressants. In clinical trials, 22.5% of Spravato patients achieved remission ...